Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6527516 | 1.00 | CHRNA7 (0.47) | CHRNA7KCNH2HTR3EHTR3BCHRNB2 | |
| Fumaric Acid SCHEMBL1542499 | 0.91 | CHRNA7 (0.42) | CHRNA7KCNH2HTR3EHTR3BCHRNB2 | |
| Fumaric Acid SCHEMBL1542496 | 0.91 | CHRNA7 (0.42) | CHRNA7KCNH2HTR3EHTR3BCHRNB2 | |
| SCHEMBL375052 | 0.84 | CHRNA7 (0.47) | CHRNA7KCNH2HTR3EHTR3BCHRNB2 | |
| SCHEMBL3840839 | 0.82 | CHRM2 (0.46) | CHRNA7CHRNB2CHRM2CHRM4CHRM5 | |
| SCHEMBL3840281 | 0.82 | CHRM2 (0.46) | CHRNA7CHRNB2CHRM2CHRM4CHRM5 | |
| SCHEMBL1542843 | 0.79 | CHRNA7 (0.42) | CHRNA7KCNH2PIK3CDLRRK2ABL1 | |
| SCHEMBL1542431 | 0.79 | CHRNA7 (0.42) | CHRNA7KCNH2PIK3CDLRRK2ABL1 | |
| SCHEMBL16656484 | 0.79 | CHRM2 (0.44) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL373301 | 0.78 | CHRNA7 (0.64) | CHRNA7HTR3EHTR3BCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | claimed |
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | claimed |
| EP-1896469-A2 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2008-03-12 | — | — | EP | claimed |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | claimed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | claimed |
| WO-2007018738-A2 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2007-02-15 | — | — | WO | claimed |
| US-7160876-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2007-01-09 | — | — | US | claimed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | claimed |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | claimed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| US-7160876-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885KCNH2 197/4885HTR3E 313/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | CHRNA7 144/4885KCNH2 26/4885HTR3E 53/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885KCNH2 197/4885HTR3E 313/4885 |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885KCNH2 210/4885HTR3E 313/4885 |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885KCNH2 210/4885HTR3E 313/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | CHRNA7 1/4885KCNH2 851/4885HTR3E 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.